Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 490 Results

Page 14 of 49« First «...12 131415 16...20 30 40...»Last »

May 2, 2022

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

May 2, 2022

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

April 25, 2022

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

April 21, 2022

Ordinary and Extraordinary General Meeting of May 12, 2022

March 21, 2022

Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States

March 21, 2022

Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years

March 14, 2022

DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference

March 9, 2022

DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

March 3, 2022

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

February 24, 2022

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

Page 14 of 49« First «...12 131415 16...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top